Companies /Healthcare

HCW Biologics Inc

NASDAQ: HCWB Biotechnology
$1.59
▼ $0.05 (−3.04%) today
Markets open · 2:28pm ET

HCWB at a Glance

Valuation
Market cap
$3.7M
Profitability
Revenue (TTM)
$6.7M
Profit margin
-83.1%
EPS (TTM)
$-19.84
Price
52-week range
$2 – $29
Street target
$48.00
Earnings
Next report
Nov 13, 2026

Headquartered in Miramar, FL Fiscal year ends December NASDAQ: HCWB hcwbiologics.com

About HCW Biologics

HCW Biologics Inc is an innovative biotechnology company dedicated to developing cutting-edge immunotherapies and vaccine technologies for pressing health challenges such as cancer and infectious diseases. Leveraging proprietary platforms that harness the power of the immune system, HCW aims to deliver transformative biopharmaceutical solutions through its robust pipeline of clinical candidates. With strategic collaborations and a strong commitment to addressing unmet medical needs, HCW Biologics is poised for significant advancements in patient care, marking it as a compelling investment opportunity in the expanding biotechnology sector.

HCWB Coverage

Frequently Asked Questions

What does HCW Biologics do?

HCW Biologics Inc is an innovative biotechnology company dedicated to developing cutting-edge immunotherapies and vaccine technologies for pressing health challenges such as cancer and infectious diseases.

What is the HCWB stock price target?

The Wall Street consensus 12-month price target for HCWB is $48.00.